Overview
ACIU market data
Price History
ACIU price chart · 1M
- O
- 2.65
- H
- 2.65
- L
- 2.46
- C
- 2.51
- Vol
- 20,363.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $2.65
- Previous Close
- $2.67
- Day High
- $2.65
- Day Low
- $2.46
- 52 Week High
- $3.00
- 52 Week Low
- $2.10
- 7 Day Return
- -5.28%
- 30 Day Return
- -11.62%
- 90 Day Return
- -5.64%
- 1 Year Return
- +2.03%
- Daily Notional Volume
- $51.1K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.70 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.61 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -246.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.10 – $4.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $250.9M · P/B 5.74 · P/S 11.88.
Company News
10 captured
Vertex Posts Positive Phase II Data on Kidney Disease DrugZacks Investment Research ·
FDA Accepts Insmed's Filing Seeking Label Expansion for ArikayceZacks Investment Research ·
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' SetbackZacks Investment Research ·
Definium Reports Second Phase III Success in Anxiety Disorder ProgramZacks Investment Research ·
Verastem Stock Skyrockets 121% in 3 Months: Here Is WhyZacks Investment Research ·
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?Zacks Investment Research ·
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary FibrosisZacks Investment Research ·